Page 1 of 7
This document provides a short summary of this study for a general audience. You can
find more information in the scientific summaries of the study. Links to those
summaries are provided at the end of this document.
Study names
Short Title: A study to assess how well mepolizumab works and how safe it is in
patients with severe bilateral nasal polyps.
Full Scientific Title: A randomised, double-blind, parallel group phase III study to assess
the clinical efficacy and safety of 100 milligrams subcutaneous mepolizumab as an add
on to maintenance treatment in adults with severe bilateral nasal polyps (SYNAPSE
study).
Study Number: 205687
Who sponsored this study?
GlaxoSmithKline (GSK)
GSK Clinical Support Help Desk
Website: clinicalsupporthd.gsk.com/contact.html
Email: GSKClinicalSupportHD@gsk.com
General information about the clinical study
When was this study done?
The study started in May 2017 and ended in December 2019.
What was the main objective of this study?
Nasal polyps are growths in the nostrils and/or sinuses. They are caused by long-term
inflammation in the inner lining of the nose. In some cases, polyps can grow in both
nostrils (bilateral nasal polyps).
Common symptoms of nasal polyps include blocked nose (nasal obstruction), runny
nose, phlegm, loss of smell, and face pain. Patients with severe bilateral nasal polyps
Use of the data and information contained in this Document is unrestricted, provided that it may not
be used in applications by others for regulatory approval of a product. While not required, when using
these data, we ask that proper credit or attribution of GSK as the source of the data be given. GSK
disclaims liability for all uses of the data by users of this Document, to the fullest extent permitted by
applicable law. No trademark, patent, or regulatory/data exclusivity rights held by GSK are waived,
licensed or otherwise affected.